Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (June 2025)
30 slides from Maia Biotechnology's investor presentation, Jun 2, 2025
Slide 1: MAIA Biotechnology: Telomere Targeting Immunotherapies for Cancer
MAIA BIOTECHNOLOGY TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA June 2025
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are "forward-looking statements." These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; sta
Slide 3: Investment Profile
INVESTMENT PROFILE (Ww) Mala NYSE American: MAIA New science for cancer therapy with dual MoA: telomere targeting and immunogenicity. *Lead molecule Ateganosine (THIO) in clinic; 2nd generation compounds in R&D ° Ateganosine approved as non-proprietary (generic) name for THIO by USAN and INN Phase 2
Slide 4: Ateganosine (THIO) Telomere Targeting Agent
Ateganosine (THIO) Telomere Targeting Agent Clinical Trial Indication Treatment Status _ Preclinical Phase 1 Phase 2 Phase 3 Rights Ateganosine > Initiating Ateganosine > Ongoing o=aa NSCLE 2L+ Libtayo® Phase 2 Worldwide ical supply rights owned agreement with by MAIA BeOne Ateganosine > = Planned U
Slide 5: Mission and Approach
MISSION AND APPROACH
Slide 6: Oncology Landscape
ONCOLOGY LANDSCAPE Cancer is the most dominant age-related disease se Population aged >80 expected to triple by 2050 a 155 million 45 countries aan At age 90: 20% will die of it \ | } 40% will be diagnosed, have life expectancy >80 years y Ne Source: UN (World Social Report, 2023); Worldometer (Life
Slide 7: Novel Treatment
NOVEL TREATMENT Ateganosine (THIO) is the only direct telomere targeting anticancer agent in clinical development
Slide 8: Treatment with Ateganosine
TREATMENT WITH ATEGANOSINE (6) MAIA NYSE American: MAIA Ateganosine (THIO, 6-thio-2'-deoxyguanosine) has a novel dual mechanism of action Followed by Immune Checkpoint Inhibitor (CPI) @ Telomere targeting © Immunogenic effect Chromosome Examples of commercially available CPIs VWaustavo’ TEVIMBRA (ce
Slide 9: THIO-101 NSCLC Trial - Rationale
THIO-101 NSCLC TRIAL - RATIONALE Preclinical Studies in NSCLC ¢ Ateganosine (THIO) followed by CPI results in 60% complete response Only 2 cycles of therapy were administered on weeks 1. and 2; no further therapy throughout the study No recurrence after long-term follow-up Anticancer immune memory h
Slide 10: NSCLC Clinical Trials
NSCLC CLINICAL TRIALS
Slide 11: THIO-101 Phase 2 Trial Design
A Multicenter, Open-label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors Expansion / Registration (NSCLC 3L) Modified 3+3 Ateganosine design 60mg . o
Slide 12: THIO-104 Phase 3 Pivotal Trial (Initiating)
THIO-104 PHASE 3 PIVOTAL TRIAL (INITIATING) A Multicenter, Open-label, Pivotal Phase 3 Trial Evaluating the Efficacy of Ateganosine (THIO) Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors and Chemothera NSCLC SE ee Eve) 3 Weeks Em Patie
Slide 13: Best Results in Third-Line NSCLC
BEST RESULTS IN THIRD-LINE NSCLC THIO-101 (Pivotal Phase 2, ongoing): Overall Survival (3L) * Median Overall Survival (OS) is at 17.8 months 1.00 © 95% CI lower bound: 12.5 months o 99% CI lower bound: 10.8 months * The treatment has been generally well-tolerated to date | %75 in this heavily pre-tr
Slide 14: Expected Efficacy in Trials in NSCLC 3L
EXPECTED EFFI IN TRIALS IN NSCLC 3L (ese: THIO-101 Phase 2 NYSE American: MAIA Ateganosine + Libtayo® (n = 137-148) * CPI + Platinum Resistant alee Se ilevliai * Prior treatment with docetaxel ORR >30%* THIO-104 Pivotal Phase 3 Ateganosine + Libtayo® (n = 150) * CPI + Platinum Resistant * Stratified
Slide 15: Planned Trials in Other Tumor Types
PLANNED TRIALS IN OTHER TUMOR TYPES
Slide 16: THIO-102 Trials (Planned)
-102 TRIALS (PLANNED) NYSE American: MAIA Multicenter, Open-label, Phase 2 Trials Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with Tislelizumab in HCC, SCLC and CRC Part A/B: Part C: Pivotal Safety/Efficacy Signal (n=~40) Phase 2 (n=~80) THIO-102-HCC ; Timune oo
Slide 17: Colorectal Rationale
COLORECTAL RATIONALE NYSE American: MAIA Preclinical Studies in Colorectal Cancer (CRC) Ateganosine (THIO) followed by CPI results in 100% complete response Only 2 cycles of therapy were 700 —e—Control —e—Atezolizumab —eTHIO —eTHIO > Atezo Tumor Volume (mm?) ~~ Ss administered on weeks 1 and 2; no n
Slide 18: SCLC & HCC - Awarded Orphan Drug Designations
SCLC & HCC —- AWARDED ORPHAN DRUG DESIGNATIONS Preclinical Studies in Small Cell Lung Cancer (SCLC) Ateganosine (THIO) is synergistic with anti-PD-1 agent Pembrolizumab in Small Cell Lung Carcinoma (H2081) in vivo in humanized murine cancer model Treatment with ateganosine (THIO) followed by Pembrol
Slide 19: Excellent Efficacy in HCC Models
EXCELLENT EFFICACY IN HCC MODELS Ateganosine (THIO) achieved complete and durable responses in Hepatocellular Carcinoma (HCC), the dominant histology in primary liver cancer (90%), in in vivo models Tumor Volume (mm?) 60054|/-<- Control <= THIO 400- 200+ 100% CR + 0 5 1015202530354045 Days After Tum
Slide 20: HCC Anti-Cancer Immune Memory
HCC ANTI-CANCER IMMUNE MEMORY When combined with immunotherapy checkpoint inhibitor Libtayo®, duration of response was further potentiated Upon rechallenge with two times more cancer cells and no additional treatment, tumor growth was completely prevented Administration of ateganosine (THIO) alone a
Slide 21: THIO-103 Trial (Planned)
THIO-103 TRIAL (PLANNED) NYSE American: MAIA A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of Ateganosine (THIO) Administered in Sequence with a Checkpoint Inhibitor (CPI) Part A/B: Part C: Pivotal PEE GE Safety/Efficacy Signal SCLC First-Line P Immune CPIs: Expansion t
Slide 22: Investment Opportunity
INVESTMENT OPPORTUNITY
Slide 23: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY Goal: New Chemical Entity (NCE) Marketing Exclusivity ¢ Ateganosine (THIO) has never been previously approved by the FDA for commercialization ¢ Robust exclusivity o US: 7 years o EU, Japan, other markets: 10 years Robust and Growing Patent Portfolio for THIO *
Slide 24: Experienced Management Team
Vlad Vitoc, MD, MBA Founder and CEO a) * 25+ years in Oncology Pharma/ Biotech: Commercial, Medical * 12 compounds launched across 20+ tumor types Leadership roles at Bayer (Nexavar), Sergei Gryaznov, PhD Chief Scientific Officer 26+ years as Scientist Expert Drug Discovery and Development, Oncology
Slide 25: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY © Developing agents for the top tumor types markets globally NSCLC (#1 WW) Mortality: 1.7M / Sales: $34B HCC Mortality: 0.8M / Sales: $3B CRC (#2 WW) Mortality: 1.0M / Sales: $20B SCLC Mortality: 0.3M / Sales: $2B Ss $50B CPIs Group (2024 Sales) 5 CPIs approved for NSC
Slide 26: Comparable Companies
COMPARABLE COMPANIES ¢ August 2022 - Bristol Myers Squibb (BMS) completed $4.1B acquisition of Turning Point Therapeutics ¢ January 2024 - BMS completed $5.8B acquisition of Mirati Therapeutics MAIA BIOTECHNOLOGY (ts) $60.4M AnaptysBioW $0.58B PXARRIVENT $0.69B /ARCUS $0.88B @ Turning Point <9 Thera
Slide 27: Expected Milestones by Trial
(Phase, Indication) THIO-104 Ph3 NSCLC 3L Enrollment Potential Filing for Early Full Potential Filing for Full Approval First Patient In (FP) Approval in US (from interim analysis) in US (from final analysis) THIO-101 Ph2 co) NSCLC 3L Enrollm. Efficacy part é a l Enrollm * Potential Filing for Accel
Slide 28: Thank You
THANK YOU Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com MAIA Biotechnology, Inc. () M A | A 444 West Lake Sireet, Suite 1700 RIOTECRIT Oa Gr Chicago, IL 60606 NYSE American: MAIA 28
Slide 29: Appendix
APPENDIX
Slide 30: Ateganosine (THIO) - U.S. FDA Designations
ATEGANOSINE (THIO) - U.S. FDA DESIGNATIONS U.S. FDA Granted 3 Orphan Drug Designations and @ 1 Rare Pediatric Disease Designation to ateganosine (THIO) + THIO has been granted 3 Orphan Drug Designations (ODD): v Hepatocellular Carcinoma (HCC, 90% of primary liver cancers) v Small Cell Lung Cancer (S
MAIA Biotechnology — Investor Presentation (June 2025) on 6ix